Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Journal: Clinical genitourinary cancer
Published: September 01, 2021
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Journal: The lancet. Gastroenterology & hepatology
Published: April 30, 2021
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
Journal: Future oncology (London, England)
Published: June 26, 2020
Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects.
Journal: British journal of clinical pharmacology
Published: June 29, 2016
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Journal: Breast (Edinburgh, Scotland)
Published: May 23, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026